X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Blexten (bilastine) is a second-generation antihistamine drug, exerts its effect through its highly selective inhibition of peripheral histamine H1 receptors for the symptomatic relief of allergic rhinitis and chronic spontaneous urticaria.
Lead Product(s): Bilastine
Therapeutic Area: Immunology Product Name: Blexten
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Aralez Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2022
Details:
Miravo Healthcare, has entered into an exclusive license and supply agreement with Orion Corporation for the exclusive right to package, distribute, market and sell Suvexx in Finland, Sweden, Denmark, Norway, Poland, Hungary, Latvia, Lithuania and Estonia.
Lead Product(s): Naproxen Sodium,Sumatriptan
Therapeutic Area: Neurology Product Name: Suvexx
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Orion Corporation
Deal Size: Undisclosed Upfront Cash: $2.0 million
Deal Type: Partnership December 21, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
